MAB885
Anti-Papillomavirus Antibody, 16L1, late protein, clone Cam Vir-1
clone Cam Vir-1, Chemicon®, from mouse
Synonym(s):
HPV
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
Cam Vir-1, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable (paraffin)
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG2a
shipped in
wet ice
Specificity
L1 (late) protein of Human Papilloma Virus type 16. Useful for studies of HPV in cervical smears and biopsies. Recognizes HPV-16 L1 by immunoprecipitation, western blotting and immunofluorescence on cells fixed in acetone or paraformaldehyde and immunoperoxidase staining of paraffin sections.
Immunogen
Beta galactosidase-HPV L1 fusion protein containing the c-terminal 60% of the L1 sequence.
Epitope: 16L1, Late Protein
Application
Anti-Papillomavirus Antibody, 16L1, late protein, clone Cam Vir-1 detects level of Papillomavirus & has been published & validated for use in IP, WB, IH(P).
Immunoprecipitation, western blotting and immunofluorescence.
Immunohistochemistry.
Shows reactivity on fixed tissue. Dilute with buffer pH 7.5 -8.0 to desired working volumes. For extensive dilution, protein containing or other stabilizing medium should be used. Final working dilutions must be determined by end user.
Immunohistochemistry.
Shows reactivity on fixed tissue. Dilute with buffer pH 7.5 -8.0 to desired working volumes. For extensive dilution, protein containing or other stabilizing medium should be used. Final working dilutions must be determined by end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
Physical form
Format: Purified
Liquid in phosphate buffer saline (PBS), pH 7.4 with 0.1% sodium azide.
Storage and Stability
Maintain at -20°C for up to 12 months. Avoid repeated freeze/thaw cycles.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Valeria Russo et al.
Pathogens (Basel, Switzerland), 9(4) (2020-04-09)
Multiple papillomatous nodules were observed scattered over the amniotic membrane in six water buffaloes that had recently aborted. Grossly, some of the nodules had multiple villous projections while others appeared as single prominent conical or cylindrical horns. Histology revealed folded
Xue Chen et al.
Human vaccines & immunotherapeutics, 14(8), 2025-2033 (2018-04-24)
Current available human papillomavirus (HPV) vaccines are based on the major capsid protein L1 virus-like particles (VLPs), which mainly induce type-specific neutralizing antibodies against vaccine types. Continuing to add more types of VLPs in a vaccine raises the complexity and
Xue Chen et al.
Oncotarget, 8(38), 63333-63344 (2017-10-04)
The neutralizing antibodies elicited by human papillomavirus (HPV) major capsid protein L1 virus-like particle (VLP)-based vaccines are largely type-specific. An HPV vaccine inducing cross-neutralizing antibodies broadly will be cost-effective and of great value. To this end, we constructed HPV16L1-58L2 chimeric
Seroprevalence of seven high-risk HPV types in The Netherlands.
Mirte Scherpenisse,Madelief Mollers,Rutger M Schepp,Hein J Boot,Hester E de Melker et al.
Vaccine null
Mingrao Ma et al.
Frontiers in bioengineering and biotechnology, 10, 1073892-1073892 (2023-01-24)
Human papillomavirus (HPV) major capsid protein L1 virus-like particles (VLPs) produced in the baculovirus system showed excellent safety and immunogenicity, but the relatively high production cost stands as a substantial barrier to extensive commercialization, especially in producing multivalent vaccines. Here
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service